Leukemia, Biphenotypic, Acute

Forecast of the full-year count, planned starts included, not rows of this table: about 6 trials starting in 2026 and about 8 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 28 percent and ran about 20 percent low against the count later registered; forecasts made before the year began were off by about 39 percent and ran about 37 percent low against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored. The 2026 forecast is below the 9 already registered with a 2026 start date: at the cutoff, 5 trials were already registered to start in October to December, more than the method's monthly average allows for, and the method does not use those planned starts.

Prediction, not a registry value: median of 36 months from start to primary completion across 44 trials still running at the 2026-10-09 snapshot; registered median of 44 months across 149 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

Status as registered on ClinicalTrials.gov. Each trial is counted once.

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.